Chunge C N, Estambale B B, Pamba H O, Chitayi P M, Munanga P N, Kang'ethe S
East Afr Med J. 1989 Nov;66(11):724-7.
Four antiamoebic drugs currently used in many Kenyan hospitals and health centres were compared for their efficacy on symptomatic luminal amoebiasis in Kiambu, Kilifi, and Machakos hospitals during this study. The drugs were; the brand metronidazole (Flagyl, May & Baker, Kenya Ltd.), the generic metronidazole (Metrozol, Cosmos Ltd., Nairobi, Kenya), the brand tinidazole (Fasigyn, Pfizer Laboratories Ltd.) and the generic tinidazole (Tynazole Laboratory and Allied Equipments, Kenya Ltd). Clinical cure was achieved in all individuals receiving any of the four drugs. Parasitological cure was better for those receiving either Flagyl or Fasigyn, than those receiving the generic counterparts. Both parasitological and clinical cures were achieved in about 50% of all those who received either Flagyl or Fasigyn. It appears that Flagyl and Fasigyn are not as efficacious as previously reported but are still much better than their generic counterparts for the treatment of symptomatic Entamoeba histolytica infections.
在本研究中，对肯尼亚许多医院和健康中心目前使用的四种抗阿米巴药物治疗基安布、基利菲和马查科斯医院有症状的肠腔阿米巴病的疗效进行了比较。这些药物分别是：品牌甲硝唑（灭滴灵，梅和贝克公司，肯尼亚有限公司）、通用甲硝唑（甲硝唑，科斯莫斯有限公司，肯尼亚内罗毕）、品牌替硝唑（速溶金，辉瑞制药有限公司）和通用替硝唑（替硝唑实验室及相关设备公司，肯尼亚有限公司）。所有接受这四种药物中任何一种治疗的个体均实现了临床治愈。接受灭滴灵或速溶金治疗的患者寄生虫学治愈率高于接受通用同类药物治疗的患者。接受灭滴灵或速溶金治疗的所有患者中，约50%实现了寄生虫学和临床治愈。看来，灭滴灵和速溶金的疗效不如先前报道的那样好，但在治疗有症状的溶组织内阿米巴感染方面仍比其通用同类药物好得多。
